File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gastro-oesophageal reflux disease in Asia: Birth of a 'new' disease?

TitleGastro-oesophageal reflux disease in Asia: Birth of a 'new' disease?
Authors
KeywordsEthnic groups
Gastro oesophageal reflux, treatment
Proton pump inhibitors, therapeutic use
Issue Date2008
PublisherAdis International Ltd. The Journal's web site is located at http://drugs.adisonline.com/
Citation
Drugs, 2008, v. 68 n. 4, p. 399-406 How to Cite?
AbstractGastro-oesophageal reflux disease (GORD) is one of the most common gastrointestinal diseases in the Western world and imposes a heavy burden on society. Although its prevalence in Asia is much lower, there is evidence that this is rapidly rising in Asia. The reported population prevalence of GORD in Eastern Asia ranges from 2.5% to 6.7% for at least weekly symptoms of heartburn and/or acid regurgitation. In general, Asians tend to have a milder spectrum of the disease. Most Asian patients have non-erosive GORD; erosive oesophagitis is less commonly seen than in the Western population. Complicated GORD, such as oesophageal stricture and Barrett's oesophagus, is seldom encountered. The mechanisms of GORD may be different in the Chinese population compared with the Western population. Chest pain is the most predominant extra-oesophageal manifestation of GORD in China, whereas an association with asthma has been shown in Japanese patients. The prevalence of GORD appears to be increasing and possible factors for GORD in Asian populations include Helicobacterpylori infection, obesity and increasing dietary fat intake. The adoption of a Western lifestyle in many developing Asian countries may account for the increasing prevalence of GORD. Proton pump inhibitors remain the most effective medical treatment for GORD. GORD will undoubtedly be a great challenge to clinicians both in primary care and in gastroenterology practice in the Asia-Pacific region in the coming years. © 2008 Adis Data Information BV. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163145
ISSN
2021 Impact Factor: 11.431
2020 SCImago Journal Rankings: 2.022
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, TKen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorLam, SKen_US
dc.date.accessioned2012-09-05T05:28:07Z-
dc.date.available2012-09-05T05:28:07Z-
dc.date.issued2008en_US
dc.identifier.citationDrugs, 2008, v. 68 n. 4, p. 399-406en_US
dc.identifier.issn0012-6667en_US
dc.identifier.urihttp://hdl.handle.net/10722/163145-
dc.description.abstractGastro-oesophageal reflux disease (GORD) is one of the most common gastrointestinal diseases in the Western world and imposes a heavy burden on society. Although its prevalence in Asia is much lower, there is evidence that this is rapidly rising in Asia. The reported population prevalence of GORD in Eastern Asia ranges from 2.5% to 6.7% for at least weekly symptoms of heartburn and/or acid regurgitation. In general, Asians tend to have a milder spectrum of the disease. Most Asian patients have non-erosive GORD; erosive oesophagitis is less commonly seen than in the Western population. Complicated GORD, such as oesophageal stricture and Barrett's oesophagus, is seldom encountered. The mechanisms of GORD may be different in the Chinese population compared with the Western population. Chest pain is the most predominant extra-oesophageal manifestation of GORD in China, whereas an association with asthma has been shown in Japanese patients. The prevalence of GORD appears to be increasing and possible factors for GORD in Asian populations include Helicobacterpylori infection, obesity and increasing dietary fat intake. The adoption of a Western lifestyle in many developing Asian countries may account for the increasing prevalence of GORD. Proton pump inhibitors remain the most effective medical treatment for GORD. GORD will undoubtedly be a great challenge to clinicians both in primary care and in gastroenterology practice in the Asia-Pacific region in the coming years. © 2008 Adis Data Information BV. All rights reserved.en_US
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://drugs.adisonline.com/en_US
dc.relation.ispartofDrugsen_US
dc.subjectEthnic groups-
dc.subjectGastro oesophageal reflux, treatment-
dc.subjectProton pump inhibitors, therapeutic use-
dc.subject.meshAsia - Epidemiologyen_US
dc.subject.meshGastroesophageal Reflux - Diagnosis - Drug Therapy - Epidemiology - Physiopathology - Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshTerminology As Topicen_US
dc.titleGastro-oesophageal reflux disease in Asia: Birth of a 'new' disease?en_US
dc.typeArticleen_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2165/00003495-200868040-00001en_US
dc.identifier.pmid18318559-
dc.identifier.scopuseid_2-s2.0-40349113721en_US
dc.identifier.hkuros150080-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40349113721&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume68en_US
dc.identifier.issue4en_US
dc.identifier.spage399en_US
dc.identifier.epage406en_US
dc.identifier.isiWOS:000254870400001-
dc.publisher.placeNew Zealanden_US
dc.identifier.scopusauthoridCheung, TK=7103334158en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridLam, SK=21534605100en_US
dc.identifier.issnl0012-6667-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats